

ASX ANNOUNCEMENT

ASX Market Announcements
Australian Securities Exchange Limited
10th Floor, 20 Bond Street
SYDNEY NSW 2000

Admedus Limited (ASX:AHZ)

ADMEDUS SECURES FUNDING THROUGH FURTHER INVESTMENT

Admedus Limited (ASX:AHZ) is pleased to announce that it has secured commitments for 20,000,000 shares to be issued to institutional and sophisticated investors at an issue price of \$0.30 per Share, raising approximately \$6 million (exclusive of costs) (Placement). These shares will be issued under the Company's ASX Listing Rule 7.1 placement capacity.

We have also issued an invitation to existing shareholders to participate in a Share Purchase Plan (SPP) that offers the opportunity to subscribe for up to A\$15,000 worth of new Admedus fully paid ordinary shares at an issue price of \$0.30 per Share.

Funds raised from both the Placement and SPP, will enable the Company to expand and progress its strategic projects, including, the acceleration of our 3D product portfolio from development to commercialisation.

Key details

- Introduces new institutional investors.
- Capital funding to accelerate commercialisation of new products in development pipeline, including TAVR.
- Placement of approximately \$6 million from high quality institutional and sophisticated investors motivated by Company turnaround and significant potential of product portfolio.
- Directors contributing 12% of Placement, subject to shareholder approval.
- SPP opportunity for existing shareholders to increase their holding at the same price as the Placement.
- Will capitalise on current momentum by increasing revenue opportunities through the introduction of multiple new products.

Admedus CEO Wayne Paterson welcomed the new investors,

“The capital raising follows growing interest from sophisticated institutional investors who value Admedus as an exciting and credible investment opportunity recognising the potential of our unique product portfolio.”

Admedus Limited
ABN 35 088 221 078

Registered Office
Level 9
301 Coronation Drive
Milton QLD 4064

Customer Service
T 1300 550 310
F 1300 880 398

International
T: +61 8 9266 0100
F: +61 8 9266 0199

E: info@admedus.com
W: www.admedus.com

Brisbane • Minneapolis
Zurich • Singapore



Over the past 18 months, Admedus has undergone a dramatic transformation and experienced unprecedented levels of growth.

During this time the Company has delivered record sales and revenue growth across ADAPT and infusion product lines, restructured key business units, secured entry into significant emerging markets and expanded product offerings with the introduction of the ground-breaking 3D shaped tissue franchise.

“Since the implementation of our new strategy, the Company has worked diligently across all areas to improve efficiencies, reduce expenses and elevate the reputation and credibility of the business within the global medtech sector,” Paterson said.

As announced recently, Admedus has submitted multiple IP applications in the US as it targets entry into the lucrative TAVR market, currently worth US\$3.5B and expected to grow to US\$5B by 2020.

“We are only just beginning to explore the full potential of our unique shaped tissue technology with 16 potential new products in the pipeline, each one leveraging the benefits of our clinically-superior ADAPT technology.”

“Momentum continues to build across the business with recent announcements including the appointment of a new VP - Development, applications for additional product patents and the signing of a Letter of Intent to provide alternative funding for our immunotherapies division.”

“Today’s placement of additional funding by high value investors will enable us to fast-track the expansion of our product range and drive future growth in revenue and market share.” Paterson concluded.

CCZ Statton Equities was the Lead Manager for the institutional placement which is expected to complete on 16 May 2018.

The SPP will be available to shareholders who were on Admedus’ register at 7.00pm AEST on Wednesday, 9 May 2018 and having a registered address in Australia or New Zealand. It will remain open until 5.00pm AEDT on Monday, 28 May 2018 (Admedus reserves its right to close the SPP early). The SPP will not be available to the Placement investors as the shares to be issued under the Placement will be issued after the Record Date.

Eligible shareholders will soon receive a separate letter and SPP Offer Booklet. Additional information and material can be accessed via www.admedus.com.

ENDS

About Admedus Limited

Admedus (ASX:AHZ) is a medical technologies company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing medical sales and distribution business. The company has

Admedus Limited
ABN 35 088 221 078

Registered Office
Level 9
301 Coronation Drive
Milton QLD 4064

Customer Service
T 1300 550 310
F 1300 880 398

International
T: +61 8 9266 0100
F: +61 8 9266 0199

E: info@admedus.com
W: www.admedus.com

Brisbane • Minneapolis
Zurich • Singapore



assets from research & development through clinical development as well as sales, marketing and distribution.

Website: www.admedus.com

Facebook: www.facebook.com/Admedus

Twitter: [@Admedus](https://twitter.com/Admedus)

For more information, please contact:

Admedus Limited

Barbara Ferres

Communications Manager

+61 7 3152 3216

communications@admedus.com

Investor Relations

WE Buchan

Scott Newstead

snewstead@we-buchan.com

03 9866 4722

Admedus Limited
ABN 35 088 221 078

Registered Office
Level 9
301 Coronation Drive
Milton QLD 4064

Customer Service
T 1300 550 310
F 1300 880 398

International
T: +61 8 9266 0100
F: +61 8 9266 0199

E: info@admedus.com
W: www.admedus.com

Brisbane • Minneapolis
Zurich • Singapore